Status:

COMPLETED

Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor

Lead Sponsor:

Children's Oncology Group

Collaborating Sponsors:

National Cancer Institute (NCI)

Conditions:

Stage I Adrenal Cortical Carcinoma AJCC v7

Stage II Adrenal Cortical Carcinoma AJCC v7

Eligibility:

All Genders

Up to 21 years

Phase:

PHASE3

Brief Summary

This phase III clinical trial is studying how well cisplatin-based chemotherapy and/or surgery works in treating young patients with stage I, stage II, stage III or stage IV adrenocortical cancer. Dru...

Detailed Description

PRIMARY OBJECTIVES: I. Describe the outcome of patients with stage I adrenocortical tumor (ACT) treated with surgery alone. II. Describe the outcome of patients with stage II ACT treated with radica...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • Histologically confirmed adrenocortical carcinoma
  • Newly diagnosed disease within the past 3 weeks
  • Any disease stage allowed
  • Lansky performance status 60-100% (for patients ≤ 16 years old)
  • Karnofsky performance status 60-100% (for patients \> 16 years old)
  • Absolute neutrophil count ≥ 750/mm\^3
  • Platelet count ≥ 75,000/mm\^3
  • Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min OR serum creatinine based on age as follows:
  • 4 mg/dL (1 month to \< 6 months)
  • 5 mg/dL (6 months to \< 1 year of age)
  • 6 mg/dL (1 to \< 2 years of age
  • 8 mg/dL (2 to \< 6 years of age)
  • 0 mg/dL (6 to \< 10 years of age)
  • 2 mg/dL (10 to \< 13 years of age)
  • 5 mg/dL (male) or 1.4 mg/dL (female) (13 to \< 16 years of age)
  • 7 mg/dL (male) or 1.4 mg/dL (female) (≥ 16 years of age)
  • Bilirubin ≤ 1.5 times upper limit of normal (ULN)
  • AST or ALT \< 2.5 times ULN
  • Shortening fraction ≥ 27% by echocardiogram OR ejection fraction ≥ 50% by radionuclide angiogram
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No previous chemotherapy for adrenocortical carcinoma

Exclusion

    Key Trial Info

    Start Date :

    May 3 2007

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    June 30 2023

    Estimated Enrollment :

    78 Patients enrolled

    Trial Details

    Trial ID

    NCT00304070

    Start Date

    May 3 2007

    End Date

    June 30 2023

    Last Update

    February 28 2024

    Active Locations (91)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 23 (91 locations)

    1

    Children's Hospital of Alabama

    Birmingham, Alabama, United States, 35233

    2

    University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama, United States, 35233

    3

    Banner University Medical Center - Tucson

    Tucson, Arizona, United States, 85719

    4

    University of Arkansas for Medical Sciences

    Little Rock, Arkansas, United States, 72205